Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

Merete Lund Hetland, Espen A Haavardsholm, Anna Rudin, Dan Nordström, Michael Nurmohamed, Bjorn Gudbjornsson, Jon Lampa, Kim Hørslev-Petersen, Till Uhlig, Gerdur Grondal, Mikkel Østergaard, Marte S Heiberg, Jos Twisk, Kristina Lend, Simon Krabbe, Lise Hejl Hyldstrup, Joakim Lindqvist, Anna-Karin Hultgård Ekwall, Kathrine Lederballe Grøn, Meliha KapetanovicFrancesca Faustini, Riitta Tuompo, Tove Lorenzen, Giovanni Cagnotto, Eva Baecklund, Oliver Hendricks, Daisy Vedder, Tuulikki Sokka-Isler, Tomas Husmark, Maud-Kristine Aga Ljoså, Eli Brodin, Torkell Ellingsen, Annika Söderbergh, Milad Rizk, Åsa Reckner Olsson, Per Larsson, Line Uhrenholt, Søren Andreas Just, David John Stevens, Trine Bay Laurberg, Gunnstein Bakland, Inge C Olsen, Ronald van Vollenhoven, NORD-STAR Study Group

Research output: Contribution to journalJournal articlepeer-review

6 Citations (Scopus)
5 Downloads (Pure)
Original languageEnglish
Article numberm4328
JournalThe BMJ
Volume371
ISSN0959-8146
DOIs
Publication statusPublished - 2 Dec 2020

Fingerprint

Dive into the research topics of 'Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial'. Together they form a unique fingerprint.

Cite this